VRC-HIVADV027-00-VP

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

AIDS VaccinesHIV InfectionsHIV-1

Phase 1

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

CompletedNCT00472719

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2007-08-31End: 2013-01-31Updated: 2021-10-14

Phase 1 Safety Study of Two Experimental HIV Vaccines

CompletedNCT00479999

National Institute of Allergy and Infectious Diseases (NIAID)AIDS Vaccines, HIV-1, HIV Infections

Start: 2007-05-24End: 2014-05-05Updated: 2019-12-16

Related Papers

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)

PLoS ONE2016-11-1516 citations

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.

2012-08-0369 citations